We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Sirona Biochem Announces Preclinical Results of Diabetes Compound

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Sirona Biochem Announces Preclinical Results of Diabetes Compound"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Sirona Biochem Corp. has announced that its lead compound for the treatment of Type 2 diabetes was effective in lowering blood glucose levels in a well-established preclinical diabetic model.

Sirona Biochem's compound, SBM-TFC-039, significantly and rapidly reduced the blood glucose level in obese diabetic rats (Zucker).

In an acute dosing study, six hours after treatment, the blood glucose level of obese diabetic rats was reduced to the level of control lean rats.

There was a strong correlation between the decrease in blood glucose level (0 to 6 hours post treatment) and the excretion of urinary glucose.

A study in normal rats also confirmed that SBM-TFC-039 triggered elimination of glucose through the urine (glycosuria) in a dose dependent manner.

SBM-TFC-039 also reduced blood glucose excursions following a glucose challenge by 34 percent compared to an untreated group. A separate safety study of SBM-TFC-039 showed the compound was well-tolerated.

SBM-TFC-039 is a sodium glucose transporter (SGLT) inhibitor. SGLT inhibitors are a new class of drug candidates for diabetes.

In the kidneys, SGLT inhibitors reduce the reabsorption of glucose into the bloodstream by eliminating excess glucose into the urine.

In addition to the SGLT inhibitor program, Sirona Biochem is continuing progress of its studies of skin lighteners and anti-aging agents for cosmetic use, inducers for recombinant protein production and adjuvants for cell and organ preservation.

All of the programs leverage the company's proprietary chemistry technology.